When there’s no clear standard of care, there’s no room for guesswork. Accurate survival estimation becomes critical to getting Phase 3 trial design right first time.
In this conference poster, Isabelle Smith, Manager, Statistics, explores how meta-analysis in clinical trials can be used to strengthen survival estimates while accounting for variability across studies.
By applying robust biostatistics and biometrics approaches, including random-effects meta-analysis and scenario planning, teams can:
- Improve sample size calculations
- Better account for heterogeneity and uncertainty
- Reduce the risk of underpowered Phase 3 trials
- Support more confident, data-driven clinical development decisions
With the right statistical expertise and scalable biometrics support, biotech and pharma teams can move beyond simplified assumptions and design trials that stand up to real-world complexity right from day one.
Click on the poster below to learn how biometrics and biostatistics improve Phase 3 success and reduce trial risk.
